Melville, N.Y.-based BioRestorative Therapies has secured a Type B meeting with the FDA to discuss an accelerated approval path for its fast-track-designated BRTX-100 program for chronic lumbar disc disease.
The meeting is scheduled for mid-December. In a Nov. 17 news release, the company said it plans to present safety and efficacy data from its ongoing phase 2 clinical trial, and request an expedited timeline to initiate a phase 3 trial in support of a biologics license application.
BioRestorative said it will share an update after reviewing the FDA’s written meeting minutes, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
